TARRYTOWN, N.Y., Feb. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page. Archived versions of the presentations will be available for thirty days after the live webcasts.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection. Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information:
Manisha Narasimhan, Ph.D.
Peter DworkinInvestor Relations
|SOURCE Regeneron Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved